



Redox-Based Probes for Protein Tyrosine Phosphatases**




Materials.  Reagents and solvents were purchased from Sigma or other commercial sources and were 
used without further purification.  DAz-1 was synthesized as previously described.[1]  YopH was 
expressed and purified as previously reported.[2]  Recombinant PTP1b protein was purchased from 
Enzo Life Sciences. 
 
Chemical Methods.  All reactions were performed under an argon atmosphere in oven-dried 
glassware.  Analytical thin layer chromatography (TLC) was carried out using Analtech Uniplate silica 
gel plates and visualized using a combination of UV, potassium permanganate, and ninhydrin staining.  
Flash chromatography was performed using silica gel (32–63 µM, 60Å pore size) from Sorbent 
Technologies Incorporated.  NMR spectra were obtained on a Varian Inova 400 (400 MHz for 1H; 100 
MHz for 13C).  1H and 13C NMR chemical shifts are reported in parts per million (ppm) referenced to 
the residual solvent peak.  High-resolution electrospray ionization (ESI) mass spectra were obtained 
with a Micromass AutoSpec Ultima Magnetic sector mass spectrometer at the University of Michigan 
Mass Spectrometry Laboratory.  Low-resolution ESI mass spectra were obtained with a Micromass 








Amino-N-(3-azidopropyl)benzamide (9):  A 2-5 mL process vial flushed with argon was charged 
with a solution of 4-aminobenzoic acid (100 mg, 0.73 mmol), EDC (280 mg, 1.46 mmol) and DMAP 
(179 mg, 1.46 mmol) in dry DMF (5 mL).  Subsequently 3-azidopropylamine (146 mg, 1.46 mmol) and 
TEA (0.204 mL, 1.46 mmol) were added to the solution.  The vial was sealed, placed into the cavity of 
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the microwave reactor and irradiated at 120 °C for 0.5 h.  The DMF was removed in vacuo and the 
resulting oil was extracted with DCM/H2O (3 x 15 mL).  The organic phases were combined, dried 
over Na2SO4, filtered, and concentrated.  Flash column chromatography was used for purification 
(EtOAc/Hexanes 6:4) to yield an oil, 4-amino-N-(3-azidopropyl)benzamide (9) (80 mg, 50%).  1H 
NMR (400 MHz, CDCl3) δ 7.57 (d, J = 8.5 Hz, 2H), 6.80 (s, 1H), 6.56 (d, J = 8 Hz, 2H), 4.14 (s, 2H), 
3.431 – 3.383 (m, 2H), 3.30 (t, J = 6.7 Hz, 2H), 1.824 – 1.757 (m, 2H).  13C NMR (100 MHz, CDCl3) δ 
167.7, 149.9, 128.6, 123.0, 49.3, 37.4, 28.8.  ESIHRMS calcd. for C10H13N5O (M + Na) 242.11, found  











N-(3-azidopropyl)-4-(3-methoxy-5-oxocyclohex-3-enecarboxamido)benzamide (10):  A 2-5 mL 
process vial flushed with argon was charged with 4-amino-N-(3-azidopropyl)benzamide (9) (363 mg, 
1.66 mmol) and TEA (0.28 mL, 1.99 mmol)in dry DMF (2.5 mL).  To this was added a solution of 3-
methoxy-5-oxocyclohex-3-enecarboxylic acid (339 mg, 1.99 mmol), EDC (382 mg, 1.99 mmol), and 
DMAP (243 mg, 1.99 mmol) in dry DMF (2.5 mL).  The vial was sealed, placed into the cavity of the 
microwave reactor and irradiated at 120 °C for 0.5 h.  The DMF was removed in vacuo and the 
resulting oil was extracted with DCM/H2O (3 x 15 mL).  The organic phases were combined, dried 
over Na2SO4, filtered, and concentrated.  Purification was completed with flash column 
chromatography (EtOAc/Hexanes 1:1 to EtOAc) to yield N-(3-azidopropyl)-4-(3-methoxy-5-
oxocyclohex-3-enecarboxamido)benzamide (10) (129 mg, 21%).  1H NMR (400 MHz, CDCl3) δ 8.95 
(s, 1H), 7.68 (d, J = 8.4 Hz, 2H), 7.62 (d, J = 8.3 Hz, 2H), 6.73 (s, 1H), 5.37 (s, 1H), 3.70 (s, 3H), 3.55 
– 3.49 (m, 2H), 3.42 (t, J = 6.5 Hz, 2H), 3.14 – 3.10 (m, 1H), 2.95 – 2.88 (m, 2H), 2.69 – 2.52 (m, 2H), 
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1.92 – 1.86 (m, 2H).  13C NMR (100 MHz, CD3OD) δ 198.8, 178.9, 168.2, 141.5, 129.4, 127.7, 118.9, 
100.8, 55.5, 48.0, 40.8, 38.7, 37.0, 36.9, 30.9, 28.4.  ESIHRMS calcd. for C18H21N5O4 (M + Na) 












(3-methoxy-5-oxocyclohex-3-enecarboxamido)benzamide (10) (129 mg, .348 mmol) was added to a 
solution of  ACN/H2O (1:1 v/v, 10 mL) with 10 mol% CAN (19 mg, .0348 mmol) and refluxed at 95 
°C for 3 h.  The reaction was cooled and concentrated.  Flash column chromatography was used for 
purification (EtOAc to EtOAc/MeOH 9:1) to yield a yellow solid (3) (123 mg, 99%).  1H NMR (400 
MHz, DMSO-d6) δ 10.22 (s, 1H), 8.41 (t, J = 5.4 Hz, 1H), 7.81 (d, J = 8.7 Hz, 2H), 7.66 (d, J = 8.7 Hz, 
2H), 5.24 (s, 1H), 3.40 (t, J = 6.7 Hz, 2H), 3.32 – 3.28 (m, 2H), 3.19 – 3.10 (m, 1H), 2.57 – 2.52 (m, 
2H), 2.50 – 2.42 (m, 2H), 1.80 – 1.73 (m, 2H).  13C NMR (100 MHz, DMSO-d6) δ 171.9, 166.1, 141.9, 









4-(((((9H-fluoren-9-yl)methoxy)carbonyl)amino)methyl)benzoic acid (11):  To a solution of 
NaHCO3 (10% w/v, 10 mL) was added 4-(aminomethyl)benzoic acid (300 mg, 1.99 mmol).  FMOC-
OSU (805 mg, 2.98 mmol) was solubilized in THF (5 mL) and added drop wise to the reaction with 
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vigorous stirring.  The mixture was stirred at RT overnight.  1 N HCl was added to acidify the solution.  
The aqueous phase was then extracted with EtOAc (3 x 15 mL), the organic phases were combined, 
dried over Na2SO4, filtered, and concentrated.  Purification was carried out by flash column 
chromatography (EtOAc/Hexanes 6:4 to EtOAc) giving the final product (11) (342 mg, 46%).  1H 
NMR (400 MHz, DMSO-d6) δ 7.95 – 7.91 (m, 2H), 7.89 (d, J = 6.9 Hz, 2H), 7.70 (d, J = 7.4 Hz, 2H), 
7.42 (t, J = 7.4 Hz, 2H), 7.34 (d, J = 3.5 Hz, 2H) 7.32 (d, J = 4.8 Hz, 2H), 4.39 (d, J = 6.7 Hz, 2H), 4.24 
(t, J = 7.7 Hz, 2H), 2.59 ( s, 1H).  13C NMR (100 MHz, DMSO-d6) δ 173.2, 167.6, 156.8, 145.3, 144.2, 
141.2, 129.7, 128.0, 127.4, 125.5, 120.5, 65.7, 47.2, 43.9, 25.6.  ESIHRMS calcd. for C23H19NO4 (M + 










(9H-fluoren-9-yl)methyl 4-((3-azidopropyl)carbamoyl)benzylcarbamate (12):  To an oven-dried 
flask, flushed with argon, was added a solution of 4-(((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)methyl)benzoic acid (11) (318 mg, .853 mmol) in anhydrous DMF (5 
mL).  TFA-Pfp was added (0.18 mL, 1.02 mmol) as well as TEA (0.143 mL, 1.02 mmol).  The mixture 
was stirred at RT for 2 h before adding 3-azidopropylamine (103 mg, 1.02 mmol) and TEA (0.14 mL, 
1.02 mmol).  The reaction mixture was then left stirring overnight at RT.  DMF was removed in vacuo 
and the resulting oil was extracted with DCM/H2O (3 x 15 mL).  The organic phases were combined, 
dried with Na2SO4, filtered, and concentrated.  Purification was carried out by flash column 
chromatography (EtOAc/Hexanes 2:8 to 6:4) yielding the product (12) (243 mg, 63%).  1H NMR (400 
MHz, DMSO-d6) δ 8.48 (t, J = 5.4 Hz, 1H), 7.89 (d, J = 7.4 Hz, 2H), 7.79 (d, J = 8.1 Hz, 2H), 7.70 (d, J 
= 7.4 Hz, 2H), 7.42 (t, J = 7.4 Hz, 2H), 7.33 (t, J = 7.4 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 4.39 – 4.35 
(m, 2H), 4.24 (t, J =6.1 Hz, 2H), 3.41 (t, J = 6.7 Hz, 2H), 3.33 – 3.30 (m, 2H), 1.82 – 1.74 (m, 2H).  13C 
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NMR (100 MHz, DMSO-d6) δ 166.5, 156.8, 144.2, 143.3, 141.1, 133.4, 128.0, 127.6, 127.4, 127.1, 
125.5, 120.5, 65.7, 48.9, 47.2, 37.04, 28.8.  ESIHRMS calcd. for C26H25N5O3 (M + Na) 478.20, found 







4-(aminomethyl)-N-(3-azidopropyl)benzamide (13):  In a round bottom flask, (9H-fluoren-9-
yl)methyl 4-((3-azidopropyl)carbamoyl)benzylcarbamate (12) (119 mg, 0.261 mmol) was added to a 
solution of ethanolamine in DCM (1:1 v/v, 5 mL) and stirred for 3 h.  The reaction mixture was washed 
with saturated NaHCO3 and extracted with DCM (3 x 15 mL).  The organic phases were combined, 
dried over Na2SO4, filtered, and concentrated.  Flash column chromatography was used for purification 
(EtOAc/Hexanes 8:2 to EtOAc/MeOH 9:1) to yield 4-(aminomethyl)-N-(3-azidopropyl)benzamide (13) 
(40 mg, 66%).  1H NMR (400 MHz, CDCl3) δ 7.73 (d, J = 8.0 Hz, 2H), 7.37 (d, J = 8.0 Hz, 2H), 6.50 
(s, 1H), 3.92 (s, 2H), 3.56 – 3.52 (m, 2H), 3.46 – 3.42 (m, 2H), 2.12 (s, 2H), 1.92 – 1.87 (m, 2H).  13C 
NMR (100 MHz, CDCl3) δ 167.4, 146.4, 132.9, 128.0, 126.9, 49.5, 45.8, 37.7, 28.7.  ESIHRMS calcd. 











N-(3-azidopropyl)-4-((3-methoxy-5-oxocyclohex-3-enecarboxamido)methyl)benzamide (14):  In an 
oven-dried round bottom flask, EDC (50 mg, .258 mmol) and DMAP (32 mg, .258 mmol) were added 
to a solution of 3-methoxy-5-oxocyclohex-3-enecarboxylic acid (44 mg, .2575 mmol) in anhydrous 
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DMF (2.5 mL) under argon.  To this was added 4-(aminomethyl)-N-(3-azidopropyl)benzamide (13) (40 
mg, 0.172 mmol) in anhydrous DMF (2.5 mL) and TEA (0.04 mL, 0.258 mmol) and the reaction was 
stirred overnight at 45 °C.  The DMF was removed in vacuo and the resulting oil was extracted using 
DCM/H2O (3 x 15 mL).  The organic phases were combined, dried with Na2SO4, filtered, and 
concentrated.  Flash column chromatography was used to purify the product (EtOAc/Hexanes 3:7 to 
EtOAc/MeOH 9:1) yielding N-(3-azidopropyl)-4-((3-methoxy-5-oxocyclohex-3-
enecarboxamido)methyl)benzamide (14) (34 mg, 52%).  1H NMR (400 MHz, CDCl3) δ 7.66 (d, J = 8.3 
Hz, 2H), 7.25 (d, J = 7.3 Hz, 2H), 5.35 (s, 1H), 4.46 (m, 2H), 3.70 (s, 3H), 3.56 – 3.51 (m, 2H), 3.44 (t, 
J = 6.5 Hz, 2H), 2.95 – 2.82 (m, 1H), 2.79 – 2.72 (m, 2H), 2.48 – 2.41 (m, 2H), 1.92 – 1.87 (m, 2H).  
13C NMR (100 MHz, CDCl3) δ 197.6, 177.5, 172.6, 167.8, 141.8, 133.4, 127.2, 101.4, 56.0, 49.3, 42.8, 











N-(3-azidopropyl)-4-((3,5-dioxocyclohex-3-enecarboxamido)methyl)benzamide (4):  In a round 
bottom flask, N-(3-azidopropyl)-4-((3-methoxy-5-oxocyclohex-3-enecarboxamido)methyl)benzamide 
(14) (100 mg, 0.260 mmol) was added to a solution of ACN/H2O (1:1 v/v, 5 mL) with 10 mol% CAN 
(14 mg, 0.026 mmol) and refluxed at 95 °C for 3 h.  Solvent was removed in vacuo.  Flash column 
chromatography was used to purify the product (EtOAc to EtOAc/MeOH 9:1) yielding (4) (89 mg, 
92%).  1H NMR (400 MHz, DMSO-d6) δ 8.53 (t, J = 5.7 Hz, 1H), 8.48 (t, J = 5.5 Hz, 1H), 7.79 (d, J = 
8.2 Hz, 2H), 7.30 (d, J = 8.1 Hz, 2H), 5.20 (s, 1H), 4.32 (d, J = 5.8 Hz, 2H), 3.40 (t, J = 6.7 Hz, 2H), 
3.34 – 3.29 (m, 2H), 3.01 – 2.97 (m, 1H), 2.46 (d, J = 10.9 Hz, 2H), 2.38 – 2.32 (m, 2H), 1.82 – 1.72 
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(m, 2H).  13C NMR (100 MHz, DMSO-d6) δ 172.7, 166.5, 143.0, 133.4, 127.6, 127.1, 103.7, 48.9, 42.2, 









A 2-5 mL process vial flushed with argon was charged with a solution of 6-amino-2-naphthoic acid (50 
mg, 0.27 mmol), EDC (58 mg, 0.30 mmol) and DMAP (52 mg, 0.30 mmol) in dry DMF (3 mL).  
Subsequently 3-azidopropylamine (54 mg, 0.54 mmol) and TEA (0.080 mL, 0.54 mmol) were also 
added to the solution.  The vial was sealed, placed into the cavity of the microwave reactor and 
irradiated at 120 °C for 0.5 h.  The DMF was removed in vacuo and the resulting oil was extracted with 
DCM/H2O (3 x 15 mL).  Flash column chromatography was used for purification (EtOAc/Hexanes 1:1) 
to yield an orange solid (15) (35 mg, 48%). 1H NMR (400MHz, CD3OD): δ 8.16 (s, 1H), 7.71 (d, 
J=8.8, 1H), 7.68 (d, J=9.2, 1H), 7.75 (d, J=8.8, 1H), 7.03 (d, J=8.4, 1H), 6.96 (d, J= 1.6, 1H), 3.47 (t, 
J=6.8, 2H), 3.40 (t, J= 6.8, 2H), 1.88 (q, J=6.4, 2H) 13C NMR (100MHz, CD3OD): δ 169.36, 147.78, 
137.02, 129.75, 127.42, 126.85, 126.29, 125.31, 123.58, 118.9, 106.93, 48.84, 36.99, 28.50. ESIHRMS 












A 2-5 mL process vial flushed with argon was charged with a solution of 3-methoxy-5-oxocyclohex-3-
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enecarboxylic acid (22 mg, 0.13 mmol), EDC (27 mg, 0.14 mmol) and DMAP (25 mg, 0.14 mmol) in 
dry DMF (3 mL).  6-amino-N-(3-azidopropyl)-2-naphthamide (15) (35 mg, 0.13 mmol) and TEA (0.02 
mL, 0.13 mmol) in dry DMF (2 mL) were then added to the solution.  The vial was sealed, placed into 
the cavity of the microwave reactor and irradiated at 120 °C for 0.5 h.  The DMF was removed in 
vacuo and the resulting oil was extracted with DCM/H2O (3 x 15 mL).  The organic phases were 
combined, dried over Na2SO4, filtered, and concentrated.  Flash column chromatography was used for 
purification (EtOAc/Hexanes 1:1 to EtOAc) to yield an orange solid (16) (33 mg, 62%).  1H NMR 
(400MHz, DMSO-d6): δ 8.60 (t, J= 4.8, 1H), 8.33 (d, J=9.2, 2H), 8.16 (d, J=6.8, 1H), 7.93 (d, J=8.8, 
1H), 7.84 (s, 1H), 7.60 (d, J= 7.2, 1H), 6.90 (d, J=6.4, 1H), 5.35 (s, 1H), 3.68 (s, 3H), 3.41 (t, J=6.8, 
2H), 3.18 (t, J= 2.4, 2H), 3.13 (s, 2H), 3.12-2.56 (m, 3H), 1.78 (q, J=6.8, 2H).  13C NMR (100MHz, 
DMSO-d6): δ 196.64, 176.97, 171.89, 167.43, 166.87, 138.42, 135.13, 130.94, 130.00, 129.18, 127.74, 
127.56, 125.10, 120.97, 115.31, 56.51, 49.00, 40.58, 37.15, 31.28, 28.88. ESIHRMS calcd. for 












In a round bottom flask, (16) (33 mg, 0.08 mmol) was added to a solution of ACN/H2O (1:1 v/v, 5 mL) 
with 10% CAN (4.4 mg, 0.008 mmol) and refluxed at 95 °C for 3 h.  The reaction was cooled and 
concentrated.  Flash column chromatography was used for purification (EtOAc to EtOAc/MeOH 9:1) 
to yield an orange solid (5) (30 mg, 92%).  1H NMR (400MHz, DMSO-d6): δ 8.29 (s, 2H), 7.92 (d, 
J=8.8, 1H), 7.84 (s,2 H),7.63 (d, J=8.8, 1H), 5.10 (s, 1H), 3.49 (t, J=4.4, 2H), 3.43 (t, J= 6.8, 2H), 2.75-
2.53 (m, 4H), 1.9 (q, J=7.2, 2H), 1.56 (t, J= 7.2, 1H). ESIHRMS calcd. for C21H21N5O4 (M + Na) 
 10 









A 2-5 mL process vial flushed with argon was charged with a solution of 4'-amino-[1,1'-biphenyl]-4-
carboxylic acid (125 mg, 0.587 mmol), EDC (122 mg, 0.646 mmol) and DMAP (110 mg, 0.30 mmol) 
in dry DMF (3 mL).  Subsequently 3-azidopropylamine (88 mg, 0.88 mmol) and TEA (0.13 mL, 0.88 
mmol) were also added to the solution.  The vial was sealed, placed into the cavity of the microwave 
reactor and irradiated at 120 °C for 0.5 h.  The DMF was removed in vacuo and the resulting oil was 
extracted with DCM and 10% (v/v) sodium bicarbonate (3 x 15 mL).  Flash column chromatography 
was used for purification (EtOAc/Hexanes 4:6) to yield a white solid (17) (39 mg, 23%).  1H NMR 
(400 MHz, CD3OD) δ 7.87 – 7.79 (m, 2H), 7.73 (dd, J = 5.8, 3.3 Hz, 1H), 7.67 – 7.60 (m, 2H), 7.45 (d, 
J = 8.5 Hz, 2H), 6.80 (d, J = 8.5 Hz, 2H), 3.48 (t, J = 6.8 Hz, 2H), 3.43 (t, J = 6.7 Hz, 2H), 1.90 (dd, J 
= 13.6, 6.9 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 167.42, 146.56, 144.27, 131.80, 129.96, 128.08, 
















A 2-5 mL process vial flushed with argon was charged with a solution of 3-methoxy-5-oxocyclohex-3-
enecarboxylic acid (23.8 mg, 0.14 mmol), EDC (26.8 mg, 0.14 mmol) and DMAP (25 mg, 0.14 mmol) 
in dry DMF (3 mL).  4'-amino-N-(3-azidopropyl)-[1,1'-biphenyl]-4-carboxamide (17) (39 mg, 0.13 
mmol) and TEA (0.02 mL, 0.13 mmol) in dry DMF (2 mL) were also added to the solution.  The vial 
was sealed, placed into the cavity of the microwave reactor and irradiated at 120 °C for 0.5 h.  The 
DMF was removed in vacuo and the resulting oil was extracted with DCM/H2O (3 x 15 mL).  The 
organic phases were combined, dried over Na2SO4, filtered, and concentrated.  Flash column 
chromatography was used for purification (EtOAc/Hexanes 6:4 to EtOAc) to yield a brown solid (18) 
(12 mg, 21%).  1H NMR (400 MHz, CDCl3) δ 7.81 (d, J = 8.4 Hz, 2H), 7.61 (d, J = 8.4 Hz,6H), 7.58 
(s, 1H), 7.55 (d, J = 8.2 Hz, 1H), 6.40 (s, 1H), 5.42 (s, 1H), 3.71 (d, J = 12.8 Hz, 3H), 3.65 – 3.56 (m, 
2H), 3.56 – 3.41 (m, 2H), 3.08 – 2.85 (m, 2H), 2.77 – 2.50 (m, 3H), 1.98 – 1.79 (m, 2H). ESIHRMS 













In a round bottom flask, (18) (12 mg, 0.027 mmol) was added to a solution of ACN/H2O (1:1 v/v, 5 
mL) with 10% CAN (1.6 mg, 0.003 mmol) and refluxed at 95 °C for 3 h.  The reaction was cooled and 
concentrated.  Flash column chromatography was used for purification (EtOAc to EtOAc/MeOH 9:1) 
to yield a yellow solid (6) (10 mg, 85%).  1H NMR (400 MHz, CD3OD) δ 8.58 (s, 1H), 7.89 (d, J = 8.6 
Hz, 2H), 7.69 (dt, J = 17.3, 8.8 Hz, 6H), 5.39 (s, 1H), 3.49 (d, J = 5.6 Hz, 2H), 3.43 (t, J = 6.7 Hz, 2H), 
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2.66 (ddd, J = 40.4, 25.6, 22.0 Hz, 3H), 2.40 – 1.97 (m, 2H), 1.95 – 1.85 (m, 2H).  ESILRMS calcd. for 









A 2-5 mL process vial flushed with argon was charged with a solution of 4-(4-aminophenoxy) benzoic 
acid  (73.5 mg, 0.32 mmol), EDC (67 mg, 0.35 mmol) and DMAP (60.4 mg, 0.35 mmol) in dry DMF 
(3 mL).  Subsequently 3-azidopropylamine (64 mg, 0.64 mmol) and TEA (0.09 mL, 0.64 mmol) were 
also added to the solution.  The vial was sealed, placed into the cavity of the microwave reactor and 
irradiated  at 120 °C for 0.5 h.  The DMF was removed in vacuo and the resulting oil was extracted 
with DCM/H2O (3 x 15 mL).  Flash column chromatography was used for purification 
(EtOAc/Hexanes 4.5:5.5) to yield a brown solid (19) (31 mg, 31%).  1H NMR (400 MHz, CDCl3) δ 
7.98 (d, J = 7.8 Hz, 2H), 6.89 – 6.74 (m, 4H), 6.66 – 6.56 (m, 2H), 3.21 – 3.15 (m, 2H), 3.13 – 3.06 (m, 
2H), 1.79 (dt, J = 12.8, 6.3 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 128.60, 121.59,116.43,116.24, 













A 2-5 mL process vial flushed with argon was charged with a solution of 3-methoxy-5-oxocyclohex-3-
enecarboxylic acid (19 mg, 0.11 mmol), EDC (21 mg, 0.11 mmol) and DMAP (19 mg, 0.11 mmol) in 
dry DMF (3 mL).  Subsequently 4-(4-aminophenoxy)-N-(3-azidopropyl)benzamide (19) (31 mg, 0.1 
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mmol) and TEA (0.01 mL, 0.1 mmol) in dry DMF (2 mL) were also added to the solution.  The vial 
was sealed, placed into the cavity of the microwave reactor and irradiated at 120 °C for 0.5 h.  The 
DMF was removed in vacuo and the resulting oil was extracted with DCM/H2O (3 x 15 mL).  The 
organic phases were combined, dried over Na2SO4, filtered, and concentrated.  Flash column 
chromatography was used for purification (EtOAc/Hexanes 1:1 to 8:2) to yield a yellow solid (20) (10 
mg, 22%) 1H NMR (400 MHz, CDCl3) δ 8.19 (s, 1H), 7.68 (t, J = 10.9 Hz, 2H), 6.90 (dd, J = 19.4, 8.4 
Hz, 4H), 6.72 – 6.57 (m, 2H), 6.33 (s, 1H), 5.39 (s, 1H), 3.70 (t, J = 12.3 Hz, 3H), 3.52 (dt, J = 18.2, 
9.0 Hz, 2H), 3.45-3.42 (m,  2H), 3.04 (s, 1H), 2.79 – 2.45 (m, 2H), 1.93 – 1.85 (m, 2H), 1.85 – 1.74 (m, 
2H).  13C NMR (100 MHz, CDCl3) δ 128.75, 121.76, 120.50, 117.40, 109.99, 101.84, 56.08, 49.57, 
49.28, 41.63, 39.62, 37.85, 35.84, 31.34, 28.74. ESILRMS calcd. for C24H25N5O5 (M + H) 464, 













N-(3-azidopropyl)-4-(4-(3-methoxy-5-oxocyclohex-3-enecarboxamido)phenoxy)benzamide (20) (10 
mg, 0.022 mmol) was added to a solution of  ACN/H2O (1:1 v/v, 10 mL) with 10 mol% CAN (1.2 mg, 
0.002 mmol) and refluxed at 95 °C for 3 h.  The reaction was cooled and concentrated.  Flash column 
chromatography was used for purification (EtOAc to EtOAc/MeOH 9:1) to yield a white solid (7) (8 
mg, 81%)   1H NMR (400 MHz, DMSO-d6) δ 8.21 (d, J = 6.9 Hz, 2H), 7.51 – 7.42 (m, 2H), 7.12 (dt, J 
= 10.8, 5.4 Hz, 2H), 6.96 (d, J = 7.3 Hz, 2H), 5.25 (s, 1H), 3.46 (s, 2H), 3.33 (s, 2H), 3.00 – 2.82 (m, 
3H), 1.83 – 1.77 (m, 2H).  13C NMR (100 MHz, DMSO-d6) δ 128.51, 125.90, 60.20, 49.02, 46.15, 








Methyl 4-((4-aminophenoxy)methyl)benzoate (21): 
In an oven-dried round bottom flask flushed with argon NaH (60% suspension 60 mg, 1.5mM) was 
added to 4-aminophenol (163.5 mg, 1.5 mmol) in dry DMF (5 mL) and stirred for 1 h at 0 °C.  Methyl 
4-(bromomethyl)benzoate (230 mg, 0.13 mmol) in dry DMF (5 mL) was slowly added to the solution.  
The reaction stirred for 2 h.  The DMF was removed in vacuo and the resulting oil was extracted with 
DCM/10% sodium bicarbonate (3 x 15 mL).  The organic phases were combined, dried over Na2SO4, 
filtered, and concentrated.  Flash column chromatography was used for purification (EtOAc/Hexanes 
1:1 to EtOAc) to yield a white solid (21) (265 mg, 62%). 1H NMR (400 MHz, CDCl3) δ 8.06 (t, J = 
14.1 Hz, 2H), 7.47 (t, J = 10.1 Hz, 2H), 6.84 – 6.77 (m, 2H), 6.67 – 6.59 (m, 2H), 5.07 (d, J = 19.9 Hz, 
2H), 3.91 (s, 3H), 3.25 (s, 2H). 13C NMR (100 MHz, CDCl3) δ 166.86, 151.58, 142.78, 140.45, 129.77, 








4-((4-aminophenoxy)methyl)benzoic acid (22): 
In a round bottom flask at 0 °C, potassium tert-butoxide (1.06 g, 11 mM) was stirred in 50 mL of ether 
for 15 min.  H2O (0.05 mL, 2.76 mmol) was then added to the slurry.  After 5 min methyl 4-((4-
aminophenoxy)methyl)benzoate (21) (265 mg, 0.92 mmol) was added and the reaction was stirred for 
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48 h.  The ether was removed in vacuo and flash column chromatography was used for purification 
(EtOAc/MeOH 9:1) to yield a yellow solid (22) (192 mg, 86%).  1H NMR (400 MHz, CD3OD) 7.97 (t, 
J = 10.0 Hz, 2H), 7.46 (d, J = 8.4 Hz, 2H), 6.87 – 6.73 (m, 2H), 6.71 (dd, J = 6.6, 2.3 Hz, 2H).  13C 
NMR (100 MHz, CD3OD) δ 152.10, 141.74, 140.05, 129.22, 126.53, 116.83, 115.57, 110.12, 69.79.  








A 2-5 mL process vial flushed with argon was charged with a solution of 4-((4-
aminophenoxy)methyl)benzoic acid (22) (100 mg, 0.41 mmol), EDC (86 mg, 0.45 mmol) and DMAP 
(60.4 mg, 0.45 mmol) in dry DMF (3 mL).  Subsequently 3-azidopropylamine (45 mg, 0.45 mmol) and 
TEA (0.06 mL, 0.45 mmol) were also added to the solution.  The vial was sealed, placed into the cavity 
of the microwave reactor and irradiated at 120 °C for 0.5 h.  The DMF was removed in vacuo and the 
resulting oil was extracted with  DCM/10% sodium bicarbonate (3 x 15 mL).  The organic phases were 
combined, dried over Na2SO4, and concentrated.  Flash column chromatography was used for 
purification (EtOAc/Hexanes 7:3) to yield a brown solid (23) (34 mg, 48%).  1H NMR (400 MHz, 
CDCl3) δ 8.25 – 8.13 (m, 2H), 6.81 – 6.72 (m, 2H), 6.66 – 6.58 (m, 2H), 6.54 (dd, J = 5.4, 1.5 Hz, 2H), 
5.00 (s, 2H), 3.75 (dd, J = 9.3, 4.5 Hz, 2H), 3.28 (dd, J = 7.0, 4.4, 1.7 Hz, 2H), 1.84 – 1.74 (m, 2H).  
13C NMR (100 MHz, CDCl3) δ 161.22, 140.77, 140.05, 127.25, 126.99, 116.31, 116.07, 70.11, 49.26, 














A 2-5 mL process vial flushed with argon was charged with a solution of 3-methoxy-5-oxocyclohex-3-
enecarboxylic acid (17 mg, 0.10 mmol), EDC (19 mg, 0.1 mmol) and DMAP (17 mg, 0.1 mmol) in dry 
DMF (3 mL).  Subsequently 4-((4-aminophenoxy)methyl)-N-(3-azidopropyl)benzamide (23) (34mg, 
0.09 mmol) and TEA (0.01 mL, 0.1 mmol) in dry DMF (2 mL) were also added to the solution.  The 
vial was sealed, placed into the cavity of the microwave reactor and irradiated at 120 °C for 0.5 h.  The 
DMF was removed in vacuo and the resulting oil was extracted with DCM/H2O (3 x 15 mL).  The 
organic phases were combined, dried over Na2SO4, filtered, and concentrated.  Flash column 
chromatography was used for purification (EtOAc/Hexanes 7:3 to EtOAc) to yield a yellow solid (24) 
(12.8 mg, 30%).  1H NMR (400 MHz, CDCl3) δ 7.72 – 7.67 (m, 2H), 7.44 (dd, J = 14.9, 8.5 Hz, 2H), 
6.98 – 6.90 (m, 2H), 6.85 (d, J = 2.2 Hz, 1H), 5.29 – 5.25 (m, 1H), 5.05 (s, 2H), 3.85 (s, 1H), 3.50 (d, J 
= 6.0 Hz, 2H), 3.39 (t, J = 6.5 Hz, 2H), 2.73 – 2.44 (m, 3H), 1.89 – 1.82 (m, 2H).  ESILRMS calcd. for 















(24) (15 mg, 0.03 mmol) was added to a solution of ACN/H2O (1:1 v/v, 10 mL) with 10% CAN (1.6 
mg, 0.003 mmol) and refluxed at 95 °C for 3 h.  The reaction was cooled and concentrated.  Flash 
column chromatography was used for purification (EtOAc to EtOAc/MeOH 9:1) to yield a white solid 
(8) (11.8 mg, 85%) 1H NMR (400 MHz, CD3OD) δ 7.81 (s, 2H), 7.61 (s, 2H), 7.03 (s, 4H), 5.12 (s, 
2H), 3.65 (s, 2H), 3.41 (s, 2H), 2.88 (s, 2H), 2.75 – 2.55 (m, 2H), 1.87 (s, 2H).  ESILRMS calcd. for 
C24H25N5O5 (M + H) 464, found 464. 
 
General procedure for PTP activity assay.  Steady-state phosphatase assays were performed by 
following the enzymatic turnover of 4-methylumbelliferyl phosphate (4-MUP) by the protein tyrosine 
phosphatase YopH or PTP1b.[3]  Briefly, to 30 µL of YopH or PTP1b (35 nM) in buffer (32 mM 
HEPES pH 7.2, 5 mM NaCl, 2.5 mM EDTA, 0.83% glycerol, 0.002% Brij-35) was added 5 µL of the 
azido-probe or DMSO control and incubated for 15 min.  The assay was initiated by addition of 20 µL 
of 4-MUP (500 µM).  The fluorescence owing to dephosphorylation of 4-MUP was measured over 15 
min at 25 °C using a SpectraMax M5 plate reader (Costar 94-well plate, λex = 358 nm, 449 nm 
emission filter). To evaluate compounds for aggregation-based inhibition, experiments were performed 
as described above except that 0.02% Triton-X100 was included in the assay buffer. 
 
LC/MS analysis of dimedone-tagged YopH.  YopH (3 µM) was incubated with dimedone (10 mM) 
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and H2O2 (30 µM) or DMSO alone in buffer (32 mM HEPES pH 7.2, 5 mM NaCl, 2.5 mM EDTA, 
0.83% glycerol, 0.002% Brij-35, 0.02% Triton X-100) with rocking for 6 h at RT.  The resulting 
samples were concentrated and exchanged into 0.1% formic acid using Amicon Ultra Centrifugal 
Filters (Amicon Ultra, 0.5 mL, 10k MWCO).  The concentrated samples were then subjected MS 
analysis.  An Agilent Eclipse XDB-C8 2.1mm x 15mm trap with mobile phases A (0.1% formic acid in 
water) and B (0.1% formic acid in acetonitrile) was used to trap, desalt and elute proteins by a linear 
gradient 5-90% of mobile phase B over 7 minutes at a flow rate of 200 uL/min.  The desalted proteins 
were eluted directly on to an electrospray linear ion trap mass spectrometer (LTQ XL, Thermo 
Scientific) to measure protein mass.  
 
Determination of the dissociation constant for inhibitor binding (Ki).  In the absence of oxidant, 
dimedone-based probes function as reversible inhibitors.  The compound-dependence of PTP inhibition 









           (1) 
 
where [I] is the inhibitor concentration, [S] is the substrate (4-MUP) in excess, and Ki is the apparent 
inhibitor binding constant.   
 
Detecting reversible PTP oxidation with azido-probes.  YopH sulfenic acid was generated by 
oxidizing protein (30 µM) with 100 eq H2O2 for 1 h at RT in buffer (32 mM HEPES pH 7.2, 5 mM 
NaCl, 2.5 mM EDTA, 0.83% glycerol, 0.002% Brij-35, 0.02% Triton-X100).  Following oxidation, 
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catalase (100 units) was added for 15 min at RT to remove excess H2O2.  Sulfenic acid modification of 
YopH was monitored by incubating protein (3 µM) with azido-probes 2-8 (0.5 mM) or DMSO (5% 
v/v) for 15 min at RT.  In some reactions, YopH (30 µM) was pretreated with dimedone (50 mM) or 
TCEP (0.9 mM) for 0.5 h at RT and then incubated with the azido-probe.  In subsequent steps, azide-
tagged YopH was conjugated to phosphine-activated biotin (p-biotin; 200 µM) via the Staudinger 
ligation for 2 h at RT.[4] To detect PTP1B oxidation, the phosphatase was treated with H2O2 and probed 
with 2, 5, 6 or DMSO (5% v/v) in buffer (50 mM HEPES pH 7.2, 1 mM EDTA, 0.05% NP-40), as 
described above. 
 
Probing sulfenic acid modification of GAPDH.  Oxidized GAPDH (15 µM) in buffer (32 mM 
HEPES pH 7.2, 5 mM NaCl, 2.5 mM EDTA, 0.83% glycerol, 0.002% Brij-35, 0.02% Triton-X100) 
was incubated with DAz-1 (0.5 mM), compound 5 or 6 (0.5 mM) or DMSO (5% v/v) for 0.5 h at 37 
°C.  Staudinger ligation was carried out by incubation of purified protein with p-biotin (200 µM) for 2 
h at 37 °C. 
 
Western blot.  Biotinylated proteins were separated by SDS−PAGE using Criterion XT 4−20% Bis-
Tris gels (BioRad) and transferred to a polyvinylidene difluoride (PVDF) membrane (BioRad).  After 
transfer, the PVDF membrane was blocked with 3% BSA in phosphate-buffered saline Tween-20 
(PBST) for 1 h at RT.  The membrane was washed with PBST (2 × 10 min) and then incubated with 
HRP-streptavidin (1:5,000 to 1:50,000; Pierce).  PVDF membrane was washed with PBST (2 × 5 min, 
1 × 10 min) and then developed with ECL Plus chemiluminescence (GE Healthcare).  GAPDH was 
probed with anti-GAPDH (1:1,000; Santa-Cruz) and rabbit anti-mouse-HRP (1:35,000; Invitrogen).  




Computational method for Autodock calculations:  Coordinates for compounds were built with 
ideal geometry in InsightII (Accelrys, Inc.), including coordinates for the Cβ and Sγ positions of the 
cysteine adduct.  The Cβ position was then overlapped on CYS403 in PDB entry 3blt.  Autodock[5] was 
used to perform a simulated annealing conformation search, keeping the Cβ atom at the 
crystallographic position and searching through rotational and torsional degrees of freedom.  Initial 
simulations revealed that the cyclic diketone formed close contacts with amino acids surrounding the 
active site, giving highly unfavorable interaction energies for all conformations.  We then modeled 
induced fit by calculating a smoothed energy function.  Smoothing is performed by calculating the 
energy potential, then scanning through the potential with a moving window, taking the minimum 
energy within the window at each point.  This has the effect of widening the favorable basins in the 
potential.  The default width for this smoothing window in AutoDock is 0.5 Å.  In the current study, we 
increased this to 1.5 Å for atoms in the cyclic diketone, and kept the default values for the variable 
portions of the compounds. 
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Figure S1.  YopH forms a covalent adduct with dimedone with 1:1 stoichiometry.  a) ESI mass spectra 
of active, unmodified YopH (33514.8 Da expected; 33514.6 Da observed).  b) ESI mass spectrum of 
H2O2-treated YopH incubated with dimedone (33653.6 Da expected; 33653.2 Da observed). The signal 
at ~908 m/z corresponds to sulfinic acid-modified YopH (33546.8 expected; 33549.7 Da observed). 
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Figure S2.  Plot of averaged initial rate versus compound 6 used to determine the averaged Ki for the 
inhibitor (n=3, error bars show the standard deviation).  Dashed line represents fit to a simple model for 




Figure S3. Detecting sulfenic acid modification of YopH.  The phosphatase was oxidized with H2O2, 
incubated with compounds 2-8 or DMSO alone (–) and analyzed by streptavidin-HRP western blot as 
described above.  Figure S3 represents a longer exposure of the autoradiographic film from Figure 4a 




Figure S4.  Compound 6 selectively modifies sulfenic acid-modified YopH.  a) YopH labeling by 
compound 6 requires oxidation by H2O2.  YopH was treated with the reducing agent TCEP, buffer 
alone, or H2O2 and then incubated with compound 6.  Following Staudinger ligation, covalent 
modification of YopH by 6 was determined by streptavidin-HRP western blot.  b) Dimedone pre-
treatment blocks YopH modification by compound 6.  YopH was treated with DMSO alone, compound 
6, or pre-treated with dimedone 1 and then incubated with 6, as described above.  Following Staudinger 
ligation, covalent modification of YopH by 6 was determined by streptavidin-HRP western blot.   
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Figure S5. Analysis of RBP selectivity for oxidized PTP1B. a) RBP 5 and 6 detect sulfenic acid in 
oxidized PTP1B with increased sensitivity over the parent compound DAz-1 2. PTP1B was oxidized 
with H2O2 and incubated with compounds 2, 5, 6 or DMSO (–) alone. Following p-biotin conjugation, 
reactions were analyzed by streptavidin-HRP western blot (top). Equal loading was verified by 
Ponceau S staining (bottom).  
 
